Francisco Trust Under Agreemen Sells 25,281 Shares of Dyadic International (NASDAQ:DYAI) Stock

Dyadic International Inc. (NASDAQ:DYAI) major shareholder Francisco Trust Under Agreemen sold 25,281 shares of the company’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $1.87, for a total transaction of $47,275.47. Following the sale, the insider directly owned 3,496,907 shares of the company’s stock, valued at approximately $6,539,216.09. This represents a 0.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Dyadic International Price Performance

DYAI stock opened at $0.94 on Monday. The company has a current ratio of 2.42, a quick ratio of 2.42 and a debt-to-equity ratio of 4.08. The firm has a 50-day moving average of $0.77 and a two-hundred day moving average of $0.83. Dyadic International Inc. has a 12 month low of $0.65 and a 12 month high of $1.35. The company has a market cap of $34.27 million, a price-to-earnings ratio of -4.09 and a beta of 1.15.

Dyadic International (NASDAQ:DYAI) last issued its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The company had revenue of $1.11 million for the quarter, compared to analyst estimates of $0.90 million. Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%. As a group, analysts forecast that Dyadic International Inc. will post 0.13 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Dyadic International in a research note on Wednesday, June 24th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Dyadic International has a consensus rating of “Hold” and a consensus target price of $3.00.

Hedge Funds Weigh In On Dyadic International

A number of institutional investors have recently bought and sold shares of the company. Apis Capital Advisors LLC acquired a new position in Dyadic International in the 3rd quarter valued at about $1,817,000. Landscape Capital Management L.L.C. purchased a new stake in shares of Dyadic International in the 3rd quarter valued at approximately $190,000. Marathon Capital Management increased its holdings in shares of Dyadic International by 142.9% during the 4th quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock worth $80,000 after buying an additional 50,000 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after buying an additional 36,266 shares during the last quarter. Finally, Bank of America Corp DE raised its position in shares of Dyadic International by 16,146.7% during the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 26,965 shares during the period. 27.95% of the stock is owned by hedge funds and other institutional investors.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.